Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates
暂无分享,去创建一个
Gina M. Butrico | K. Petersen | S. Dufour | G. Shulman | L. Goedeke | G. Cline | Xian‐Man Zhang | K. Chng | P. Kievit | Rachel J. Perry | Liang Peng | Valle Montalvo-Romeral | R. Perry
[1] K. Petersen,et al. Regulation of hepatic mitochondrial oxidation by glucose-alanine cycling during starvation in humans. , 2019, The Journal of clinical investigation.
[2] M. Heikenwalder,et al. From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.
[3] Lu Qi,et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans , 2019, Science Translational Medicine.
[4] G. Shulman,et al. Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes. , 2019, Annual review of pharmacology and toxicology.
[5] G. Shulman,et al. Acetyl‐CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents , 2018, Hepatology.
[6] G. Shulman,et al. Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. , 2018, Cell reports.
[7] K. Petersen,et al. Mechanisms by which a Very-Low-Calorie Diet Reverses Hyperglycemia in a Rat Model of Type 2 Diabetes. , 2018, Cell metabolism.
[8] G. Shulman,et al. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. , 2018, Cell metabolism.
[9] Michael J. Marcel,et al. Insulin receptor Thr 1160 phosphorylation mediates lipid-induced hepatic insulin resistance , 2018 .
[10] L. Henry,et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.
[11] A. Comuzzie,et al. Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field. , 2017, ILAR journal.
[12] Gina M. Butrico,et al. Non-invasive assessment of hepatic mitochondrial metabolism by positional isotopomer NMR tracer analysis (PINTA) , 2017, Nature Communications.
[13] G. Shulman,et al. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. , 2017, Trends in pharmacological sciences.
[14] S. L. la Fleur,et al. Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans , 2017, Cell reports.
[15] K. Petersen,et al. A controlled‐release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] K. Petersen,et al. A Non-invasive Method to Assess Hepatic Acetyl-CoA In Vivo. , 2017, Cell metabolism.
[17] M. Erion,et al. Phenotyping of adipose, liver, and skeletal muscle insulin resistance and response to pioglitazone in spontaneously obese rhesus monkeys. , 2017, American journal of physiology. Endocrinology and metabolism.
[18] K. Kavanagh,et al. Fatty Liver Promotes Fibrosis In Monkeys Consuming High Fructose , 2016, Obesity.
[19] K. Chng,et al. Hepatic Steatosis and Fibrosis in Obese, Dysmetabolic and Diabetic Nonhuman Primates Quantified by Noninvasive Echography , 2017 .
[20] Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test. , 2016, Journal of visualized experiments : JoVE.
[21] Michael J. Marcel,et al. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. , 2016, The Journal of clinical investigation.
[22] K. Petersen,et al. Assessment of Hepatic Mitochondrial Oxidation and Pyruvate Cycling in NAFLD by (13)C Magnetic Resonance Spectroscopy. , 2016, Cell metabolism.
[23] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[24] A. Roverato,et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis , 2016, Journal of gastroenterology and hepatology.
[25] K. Petersen,et al. Propionate Increases Hepatic Pyruvate Cycling and Anaplerosis and Alters Mitochondrial Metabolism* , 2016, The Journal of Biological Chemistry.
[26] K. Chng,et al. Left ventricular diastolic dysfunction in nonhuman primate model of dysmetabolism and diabetes , 2015, BMC Cardiovascular Disorders.
[27] A. Burt,et al. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification , 2015, Seminars in Liver Disease.
[28] G. Shulman,et al. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats , 2015, Science.
[29] G. Shulman,et al. Niclosamide ethanolamine improves blood glycemic control and reduces hepatic steatosis in mice , 2014, Nature Network Boston.
[30] G. Shulman,et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans , 2014, Proceedings of the National Academy of Sciences.
[31] M. Reitman,et al. The Chemical Uncoupler 2,4-Dinitrophenol (DNP) Protects against Diet-induced Obesity and Improves Energy Homeostasis in Mice at Thermoneutrality* , 2014, The Journal of Biological Chemistry.
[32] Michael J. MacDonald,et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase , 2014, Nature.
[33] Douglas L. Rothman,et al. Direct assessment of hepatic mitochondrial oxidative and anaplerotic fluxes in humans using dynamic 13C magnetic resonance spectroscopy , 2013, Nature Medicine.
[34] G. Shulman,et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. , 2013, Cell metabolism.
[35] V. Adam,et al. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. , 2012, Oncology letters.
[36] S. Klein,et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. , 2012, Gastroenterology.
[37] Robert V Farese,et al. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. , 2012, Cell metabolism.
[38] H. J. Harwood,et al. Nonhuman Primates and other Animal Models in Diabetes Research , 2012, Journal of diabetes science and technology.
[39] H. J. Harwood,et al. Diabetes and Obesity Research using Nonhuman Primates , 2012 .
[40] S. Burgess,et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. , 2011, Cell metabolism.
[41] B. Swinburn,et al. The global obesity pandemic: shaped by global drivers and local environments , 2011, The Lancet.
[42] P. Dargan,et al. 2,4-Dinitrophenol (DNP): A Weight Loss Agent with Significant Acute Toxicity and Risk of Death , 2011, Journal of Medical Toxicology.
[43] Enzo Bonora,et al. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.
[44] Ajit S. Divakaruni,et al. Mitochondrial proton and electron leaks. , 2010, Essays in biochemistry.
[45] A. Kowaltowski,et al. Mild mitochondrial uncoupling in mice affects energy metabolism, redox balance and longevity , 2008, Aging cell.
[46] K. Petersen,et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.
[47] M. Birnbaum,et al. Protein Kinase C θ Inhibits Insulin Signaling by Phosphorylating IRS1 at Ser1101* , 2004, Journal of Biological Chemistry.
[48] D. Befroy,et al. Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.
[49] M. Birnbaum,et al. Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101). , 2004, The Journal of biological chemistry.
[50] Roberto Colombo,et al. Protein carbonyl groups as biomarkers of oxidative stress. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[51] K. Petersen,et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.
[52] Margaret S. Wu,et al. Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.
[53] G. Shulman,et al. Mechanism of Insulin Resistance in A-ZIP/F-1 Fatless Mice* , 2000, The Journal of Biological Chemistry.
[54] J. Goldstein,et al. The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.
[55] David Leake,et al. Current State of the Field , 1995 .
[56] D. Hardie,et al. Regulation of HMG‐CoA reductase: identification of the site phosphorylated by the AMP‐activated protein kinase in vitro and in intact rat liver. , 1990, The EMBO journal.
[57] S. Simkins. DINITROPHENOL AND DESICCATED THYROID IN THE TREATMENT OF OBESITY: A COMPREHENSIVE CLINICAL AND LABORATORY STUDY , 1937 .
[58] R. Koch,et al. Dinitrophenol on Liver Function. , 1935, California and western medicine.
[59] M. Tainter,et al. DINITROPHENOL IN THE TREATMENT OF OBESITY: FINAL REPORT , 1935 .
[60] M. Tainter,et al. METABOLIC ACTIONS OF DINITROPHENOL: WITH THE USE OF BALANCED AND UNBALANCED DIETS , 1933 .
[61] M. Tainter,et al. USE OF DINITROPHENOL IN OBESITY AND RELATED CONDITIONS: A PROGRESS REPORT , 1933 .